JP2010540519A5 - - Google Patents

Download PDF

Info

Publication number
JP2010540519A5
JP2010540519A5 JP2010526924A JP2010526924A JP2010540519A5 JP 2010540519 A5 JP2010540519 A5 JP 2010540519A5 JP 2010526924 A JP2010526924 A JP 2010526924A JP 2010526924 A JP2010526924 A JP 2010526924A JP 2010540519 A5 JP2010540519 A5 JP 2010540519A5
Authority
JP
Japan
Prior art keywords
composition
drug
dose
package
per day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010526924A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010540519A (ja
JP5460600B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/011026 external-priority patent/WO2009045291A2/en
Publication of JP2010540519A publication Critical patent/JP2010540519A/ja
Publication of JP2010540519A5 publication Critical patent/JP2010540519A5/ja
Application granted granted Critical
Publication of JP5460600B2 publication Critical patent/JP5460600B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010526924A 2007-09-28 2008-09-24 肥満症治療における肥満細胞安定化薬 Active JP5460600B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US96040807P 2007-09-28 2007-09-28
US60/960,408 2007-09-28
PCT/US2008/011026 WO2009045291A2 (en) 2007-09-28 2008-09-24 Mast cell stabilizers in the treatment of obesity

Publications (3)

Publication Number Publication Date
JP2010540519A JP2010540519A (ja) 2010-12-24
JP2010540519A5 true JP2010540519A5 (enExample) 2012-11-08
JP5460600B2 JP5460600B2 (ja) 2014-04-02

Family

ID=40523802

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010526924A Active JP5460600B2 (ja) 2007-09-28 2008-09-24 肥満症治療における肥満細胞安定化薬

Country Status (5)

Country Link
US (2) US8445435B2 (enExample)
EP (1) EP2205243A4 (enExample)
JP (1) JP5460600B2 (enExample)
CN (1) CN101808642B (enExample)
WO (1) WO2009045291A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8445437B2 (en) * 2006-07-27 2013-05-21 The Brigham And Women's Hospital, Inc. Treatment and prevention of cardiovascular disease using mast cell stabilizers
EP3309556B1 (en) * 2009-06-25 2020-04-08 Prometheus Biosciences, Inc. Methods for diagnosing irritable bowel syndrome
CN102204871A (zh) * 2011-06-01 2011-10-05 王青 一种减肥用组合物
CN102846679A (zh) * 2012-08-14 2013-01-02 王青 一种具有减肥作用的组合物
EP3725311A1 (en) 2014-02-10 2020-10-21 Respivant Sciences GmbH Methods for the treatment of lung diseases with mast cell stabilizers
EP3653207A1 (en) 2014-02-10 2020-05-20 Respivant Sciences GmbH Mast cell stabilizers treatment for systemic disorders
US10265296B2 (en) 2015-08-07 2019-04-23 Respivant Sciences Gmbh Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders
EP3331522A1 (en) 2015-08-07 2018-06-13 Patara Pharma LLC Methods for the treatment of mast cell related disorders with mast cell stabilizers
US20190016680A1 (en) 2016-01-14 2019-01-17 Beth Israel Deaconess Medical Center, Inc. Mast-cell modulators and uses thereof
CN110139646A (zh) 2016-08-31 2019-08-16 瑞思皮万特科学有限责任公司 用于治疗由特发性肺纤维化引起的慢性咳嗽的色甘酸组合物
WO2018067341A1 (en) 2016-10-07 2018-04-12 Patara Pharma, LLC Cromolyn compositions for treatment of pulmonary fibrosis
KR102543789B1 (ko) * 2021-03-08 2023-06-20 주식회사 온코크로스 토르세미드 및 크로몰린을 포함하는 대사질환 예방 또는 치료용 조성물

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4634699A (en) 1983-11-30 1987-01-06 Burroughs Wellcome Co. Branched chain phenothiazine
US4923892A (en) 1985-08-17 1990-05-08 Burroughs Wellcome Co. Tricyclic aromatic compounds
GB8520662D0 (en) 1985-08-17 1985-09-25 Wellcome Found Tricyclic aromatic compounds
AU6786794A (en) 1993-05-10 1994-12-12 Sepracor, Inc. Methods and compositions using optically pure (+)-zileuton
US5624949A (en) 1993-12-07 1997-04-29 Eli Lilly And Company Protein kinase C inhibitors
WO1997038693A1 (en) 1996-04-18 1997-10-23 Alcon Laboratories, Inc. Calcium channel blockers as human conjunctival mast cell degranulation inhibitors for treating ocular allergic conditions
WO1998056381A1 (en) 1997-06-09 1998-12-17 Bridge Pharma, Inc. Compounds with combined antihistaminic and mast cell stabilizing activities, intended for ophthalmic use
EP1005336A4 (en) 1997-07-09 2001-01-17 Androsolutions Inc IMPROVED METHODS AND COMPOSITIONS FOR TREATING MALE ERECTIONAL DISORDERS
US6232297B1 (en) 1999-02-01 2001-05-15 University Of Virginia Patent Foundation Methods and compositions for treating inflammatory response
US6777429B1 (en) 1999-07-23 2004-08-17 Novartis Ag Ophthalmic composition
US20040092511A1 (en) * 1999-12-10 2004-05-13 Billstein Stephan Anthony Pharmaceutical combinations and their use in treating gastrointestinal and abdominal viscera disorders
US20040115290A1 (en) 2001-06-20 2004-06-17 Tripp Matthew L. Modulation of inflammation by hops fractions and derivatives
AU2002352974A1 (en) * 2001-11-29 2003-06-10 Emisphere Technologies, Inc. Formulations for oral administration of cromolyn sodium
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
AU2003225964B2 (en) * 2002-03-28 2008-11-20 Merck Sharp & Dohme Corp. Substituted 2,3-diphenyl pyridines
DE10301371A1 (de) 2003-01-16 2004-08-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische Kombination zur Prophylaxe oder Therapie von kardiovaskulären, kardiopulmonalen, pulmonalen oder renalen Krankheiten
US20060263350A1 (en) * 2003-09-26 2006-11-23 Fairfield Clinical Trials Llc Combination antihistamine medication
CA2607272A1 (en) 2005-05-09 2006-11-16 Azur Pharma Limited Formulations of mast cell stabilizing agents for delivery to the colon
EP2001861A2 (en) 2006-02-21 2008-12-17 Critical Therapeutics, Inc. New crystal forms and pharmaceutical compositions of (+)-r-zileuton
US8445437B2 (en) * 2006-07-27 2013-05-21 The Brigham And Women's Hospital, Inc. Treatment and prevention of cardiovascular disease using mast cell stabilizers

Similar Documents

Publication Publication Date Title
JP2010540519A5 (enExample)
JP6391071B2 (ja) シスタチオニン−γ−リアーゼ（ＣＳＥ）阻害剤
US20130224151A1 (en) Use of FAAH Inhibitors for Treating Abdominal, Visceral and Pelvic Pain
JP2015526458A5 (enExample)
RU2011139643A (ru) Способ лечения неалкогольного стеатогепатита повышенными дозами урсодезоксихолевой кислоты
JP2004519469A5 (enExample)
JP2008515905A5 (enExample)
EP2877175A2 (en) Use of cse inhibitors for the treatment of cutaneous injuries or conditions and sleep-related breathing disorders
BRPI0912607A2 (pt) medicamento consistindo em uso concomitante ou combinação de inibidor de dpp-iv e outro medicamento para o diabete
JP2007530493A5 (enExample)
JP2006518731A5 (enExample)
RU2014113334A (ru) Применение ингибитора ароматазы для лечения гипогонадизма и родственных заболеваний
JP2014508758A5 (enExample)
CN106714819A (zh) 治疗普拉德‑威利综合征的方法
EP1938814A1 (en) Pharmaceutical for protection of motor nerve in patient with amyotrophic lateral sclerosis
US20170151222A1 (en) Snoring treatment
RU2013112890A (ru) Терапевтическое применение 1-[2-(2,4-диметилфенилсульфанил)фенил]пиперазина
JP2009506043A5 (enExample)
WO2006116470A1 (en) Use of metformin to counteract weight gain associated with aripiprazole or ziprasidone treatment
WO2004017973A1 (ja) 統合失調症治療剤
JP6227535B2 (ja) 脂質異常症の予防又は治療薬
WO2018025049A1 (en) New use of n,n-bis-2-mercaptoethyl isophthalamide
RU2006110550A (ru) Применение окскарбазепина для лечения диабетической нейропатической боли и для улучшения сна
RU2414895C2 (ru) Способ лечения поражения печени у больных лепрой
RU2012114097A (ru) Терапевтический агент против хронической боли